BCL2 and glioblastoma: Additionally, such studies could investigate whether case-specific predictions could be made, possibly with the assistance of mathematical modelling, on whether the further addition of Bcl-2-family member antagonists to the treatment regimen could efficiently sensitize TRAIL/TL32711-resistant GBM tissues to treatment.